The DOI matches its Crossref record; 157 of the 162 references it cites were found in a registry or an index.
RAS Proteins and Their Regulators in Human Disease
Open accessAbstract
RAS proteins are binary switches, cycling between ON and OFF states during signal transduction. These switches are normally tightly controlled, but in RAS-related diseases, such as cancer, RASopathies, and many psychiatric disorders, mutations in the RAS genes or their regulators render RAS proteins persistently active. The structural basis of the switch and many of the pathways that RAS controls are well known, but the precise mechanisms by which RAS proteins function are less clear. All RAS biology occurs in membranes: a precise understanding of RAS' interaction with membranes is essential to understand RAS action and to intervene in RAS-driven diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In particular, farnesylation at the position 185 cysteine residue results in KRAS anchoring at the plasma membrane, initiating the activation of KRAS and its downstream signaling42.”
From Mechanisms of KRAS inhibitor resistance in KRAS-mutant colorectal cancer harboring Her2 amplification and aberrant KRAS localization (2025) · cites this paper as [42]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Post-translational modification of KRAS plays an important role in KRAS–MAPK pathway activation.”
From Mechanisms of KRAS inhibitor resistance in KRAS-mutant colorectal cancer harboring Her2 amplification and aberrant KRAS localization (2025) · cites this paper as [42]
The cited source says what the claim attributes to it.
In the citing paper
“KRAS is one of the most frequently mutated oncogenes in cancer, yet efforts to directly target KRAS have been mostly unsuccessful because initial analyses of KRAS proteins indicated that they lack a clear pocket to which small molecules can bind with high affinity [1, 2].”
From Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor (2022) · cites this paper as [2]
The cited source says what the claim attributes to it.
In the citing paper
“Although KRAS mutations are often collectively classified as a single oncogenic entity, distinct KRAS alleles exhibit substantial biochemical and functional heterogeneity [1,4,12].”
From Precision Targeting of KRAS-Mutant Cancers: Beyond G12C Toward G12D and Pan-RAS Therapeutic Strategies (2026) · cites this paper as [4]
In the citing paper
“Mutational activation of KRAS promotes the initiation and progression of cancers, especially in the colorectum, pancreas, lung, and blood plasma, with varying prevalence of specific activating missense mutations.”
From The origins and genetic interactions of KRAS mutations are allele- and tissue-specific (2021) · cites this paper as [1]
In the citing paper
“However, it is frequently mutated in only a handful of cancers, with the highest frequencies in colorectal adenocarcinoma (COAD), lung adenocarcinoma (LUAD), multiple myeloma (MM), and pancreatic adenocarcinoma (PAAD).”
From The origins and genetic interactions of KRAS mutations are allele- and tissue-specific (2021) · cites this paper as [1]
In the citing paper
“KRAS is one of the most commonly mutated genes in cancer1,2”
From The origins and genetic interactions of KRAS mutations are allele- and tissue-specific (2021) · cites this paper as [1]
In the citing paper
“When mutated at one of its four hotspot codons—12, 13, 61, or 146—activated KRAS protein hyperactivates many downstream effector pathways, such as the MAPK and PI3K-AKT signaling pathways1”
From The origins and genetic interactions of KRAS mutations are allele- and tissue-specific (2021) · cites this paper as [1]
In the citing paper
“As protein tyrosine phosphorylation plays an essential role in multiple intracellular processes, SHP2 is involved in the regulation of multiple signaling pathways, including those involved in cancer cells, such as RAS-MAPK, PI3K-AKT and JAK-STAT pathways.”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [261]
In the citing paper
“RAS acts as a molecular switch, transmitting signals of cell growth and differentiation by binding to GTP or GDP and switching between active and inactive states.261”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [261]
In the citing paper
“abnormalities in components of the RAS pathway, including activating RAS mutations, are common across a diverse range of malignancies”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [4]
In the citing paper
“The RAS family GTPases, KRAS, NRAS and HRAS, cycle between GTP-loaded ‘on’ and GDP-loaded ‘off’ states4,6, involving the action of RAS-guanine nucleotide exchange factors (RAS-GEFs) and RAS-GTPase-activating proteins (RAS-GAPs), respectively.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [4]
In the citing paper
“Almost all cancer-associated RAS mutations (~95%) affect codon 12, 13 or 61, and lead to a markedly increased basal RAS-GTP:RAS-GDP ratio and constitutive activation of RAS effectors4,6.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [4]
In the citing paper
“When mutated, oncogenic RAS remains preferentially in the active GTP-bound state, whereas GTP hydrolysis by its GTPase function and enzymes such as GTPase-activating proteins, is compromised1,2.”
From The metabolic landscape of RAS-driven cancers from biology to therapy (2021) · cites this paper as [1]
In the citing paper
“KRAS in particular, is among the most frequently mutated oncogenes in cancer and is commonly associated with therapeutic resistance and poor prognosis1,5,6.”
From The metabolic landscape of RAS-driven cancers from biology to therapy (2021) · cites this paper as [1]
In the citing paper
“These mutations dramatically shift the equilibrium of Ras protein to exist mostly in the GTP-bound state and effectively uncouple Ras proteins from upstream receptor inputs and drive constitutive signaling to downstream Ras effector pathways (13).”
From KRAS mutation in pancreatic cancer (2021) · cites this paper as [13]
In the citing paper
“On the one hand, the affinity of KRAS and GTP is at the pM level, while the concentration of GTP in cells is up to 0.5 μM.”
From Targeting KRAS mutant cancers: from druggable therapy to drug resistance (2022) · cites this paper as [18]
In the citing paper
“It is difficult to achieve effective competition like protein kinase inhibitors [18, 19].”
From Targeting KRAS mutant cancers: from druggable therapy to drug resistance (2022) · cites this paper as [18]
In the citing paper
“Oncogenic KRAS can activate various downstream effector pathways, and the best characterized are phosphatidylinositol 3-kinase (PI3K) and mitogen-activated protein kinases (MAPK) (23–25).”
From New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness (2019) · cites this paper as [24]
In the citing paper
“we recognize that these elements have a substantial influence on KRAS dynamics [53,54] and signaling [55].”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557
GEFs and GAPs: Critical Elements in the Control of Small G Proteins
Bos, J. L., Rehmann, H., & Wittinghofer, A. (2007) · Cell · doi:10.1016/j.cell.2007.05.018 · Cited by 1,903
The Guanine Nucleotide-Binding Switch in Three Dimensions
Vetter, I. R., & Wittinghofer, A. (2001) · Science · doi:10.1126/science.1062023 · Cited by 1,875
All ras proteins are polyisoprenylated but only some are palmitoylated
Hancock, J. F., Magee, A. I., Childs, J. E., & Marshall, C. J. (1989) · Cell · doi:10.1016/0092-8674(89)90054-8 · Cited by 1,775
The Ras-RasGAP Complex: Structural Basis for GTPase Activation and Its Loss in Oncogenic Ras Mutants
Scheffzek, K., Ahmadian, M. R., Kabsch, W., Wiesmüller, L., Lautwein, A., Schmitz, F., & Wittinghofer, A. (1997) · Science · doi:10.1126/science.277.5324.333 · Cited by 1,543
Regulation of Small GTPases by GEFs, GAPs, and GDIs
Cherfils, J., & Zeghouf, M. (2013) · Physiological Reviews · doi:10.1152/physrev.00003.2012 · Cited by 1,245
A Cytoplasmic Protein Stimulates Normal N- ras p21 GTPase, But Does Not Affect Oncogenic Mutants
Trahey, M., & McCormick, F. (1987) · Science · doi:10.1126/science.2821624 · Cited by 1,211
Self-citationDistinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas
Cancer Genome Atlas Research Network, Campbell, J. D., Alexandrov, A., Kim, J., Wala, J., Berger, A. H., Pedamallu, C. S., Shukla, S. A., Guo, G., Brooks, A. N., et al. (2016) · Nature Genetics · doi:10.1038/ng.3564 · Cited by 1,200
Milburn, M. V., Tong, L., deVos, A. M., Brünger, A. T., Yamaizumi, Z., Nishimura, S., & Kim, S. (1990) · Science · doi:10.1126/science.2406906 · Cited by 1,062
Requirement for Ras in Raf activation is overcome by targeting Raf to the plasma membrane
Leevers, S. J., Paterson, H. F., & Marshall, C. J. (1994) · Nature · doi:10.1038/369411a0 · Cited by 1,011
Flagged first, then by citations
5 of the 162 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 401–500 of 1,005
The current landscape of using direct inhibitors to target KRASG12C-mutated NSCLC
Batrash, F., Kutmah, M., & Zhang, J. (2023) · Experimental Hematology and Oncology · doi:10.1186/s40164-023-00453-8 · Cited by 42
Modelling Cooperative Tumorigenesis in Drosophila
Richardson, H. E., & Portela, M. (2018) · BioMed Research International · doi:10.1155/2018/4258387 · Cited by 41
Kizilboga, T., Baskale, E. A., Yıldız, J., Akçay, İ. M., Zemheri, E. I., Can, N. D., Özden, C., Demir, S., Ezbercı, F., & Doğanay, G. D. (2019) · BMC Cancer · doi:10.1186/s12885-019-6477-4 · Cited by 37
Rai, A., Greening, D. W., Xu, R., Suwakulsiri, W., & Simpson, R. J. (2020) · PROTEOMICS · doi:10.1002/pmic.202000016 · Cited by 36
Upadhya, A., Yadav, K. S., & Misra, A. R. (2020) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2021.1825377 · Cited by 38
Lysine Fatty Acylation: Regulatory Enzymes, Research Tools, and Biological Function
Komaniecki, G., & Lin, H. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.717503 · Cited by 37
Targeting RAS phosphorylation in cancer therapy: Mechanisms and modulators
Qiu, Y., Wang, Y., Chai, Z., Ni, D., Li, X., Pu, J., Chen, J., Zhang, J., Lu, S., Lv, C., et al. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.02.014 · Cited by 39
LncRNA Biomarkers of Inflammation and Cancer
Reggiardo, R. E., Maroli, S. V., & Kim, D. H. (2022) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-92034-0_7 · Cited by 40
Michelotti, A., de Scordilli, M., Bertoli, E., Carlo, E. D., Conte, A. D., & Bearz, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23126748 · Cited by 37
Anastasiou, P., Moore, C., Rana, S., Tomaschko, M., Pillsbury, C. E., de Castro, A., Boumelha, J., Mugarza, E., Trécesson, S. D. C., Mikolajczak, A., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-52324-3 · Cited by 38
Emerging landscape of KRAS inhibitors in cancer treatment
Riedl, J. M., Matsubara, H., McNeil, R., Patel, P. S., de la Cruz, F. F., Gulhan, D., & Corcoran, R. B. (2026) · Cancer Cell · doi:10.1016/j.ccell.2026.01.001 · Cited by 41
Vendramini, E., Bomben, R., Pozzo, F., Benedetti, D., Bittolo, T., Rossi, F. M., Bo, M. D., Rabe, K. G., Pozzato, G., Zaja, F. F., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0444-6 · Cited by 36
Dissemination of RasV12-transformed cells requires the mechanosensitive channel Piezo
Lee, J., Cabrera, A. J. H., Nguyen, C. M. T., & Kwon, Y. V. (2020) · Nature Communications · doi:10.1038/s41467-020-17341-y · Cited by 35
Promotion of cancer cell stemness by Ras
Chippalkatti, R., & Abankwa, D. (2021) · Biochemical Society Transactions · doi:10.1042/bst20200964 · Cited by 34
Drug resistance in targeted cancer therapies with RAF inhibitors
Degirmenci, U., Yap, J., Sim, Y. R. M., Qin, S., & Hu, J. (2021) · Cancer Drug Resistance · doi:10.20517/cdr.2021.36 · Cited by 36
Feasibility of using NF1-GRD and AAV for gene replacement therapy in NF1-associated tumors
Bai, R.-Y., Esposito, D., Tam, A. J., McCormick, F., Riggins, G. J., Wade Clapp, D., & Staedtke, V. (2019) · Gene Therapy · doi:10.1038/s41434-019-0080-9 · Cited by 38
Self-citationChen, X., Yang, H. T., Zhang, B. D., Phillips, J. W., Cheng, D., Rigo, F., Witte, O. N., Xing, Y., & Black, D. L. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2220190120 · Cited by 34
Xiong, H., Yu, H., Zhang, J., Fang, L., Wu, D., Lin, X., & Xie, C. (2023) · Military Medical Research · doi:10.1186/s40779-023-00501-8 · Cited by 37
CD44: A New Prognostic Marker in Colorectal Cancer?
Ziranu, P., Pretta, A., Aimola, V., Cau, F., Mariani, S., D’Agata, A. P., Codipietro, C., Rizzo, D., Dell’Utri, V., Sanna, G., et al. (2024) · Cancers · doi:10.3390/cancers16081569 · Cited by 38
Sudhakar, N., Yan, L., Qiryaqos, F., Engstrom, L. D., Laguer, J., Calinisan, A., Hebbert, A., Waters, L. M., Moya, K., Bowcut, V., et al. (2024) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-23-0870 · Cited by 37
Czyzyk, D. J., Yan, W., Messing, S. A. J., Gillette, W., Tsuji, T., Yamaguchi, M., Furuzono, S., Turner, D. M., Esposito, D., Nissley, D. V., et al. (2025) · Nature Communications · doi:10.1038/s41467-024-55766-x · Cited by 37
Self-citationTumor promoter TPA activates Wnt/β-catenin signaling in a casein kinase 1-dependent manner
Su, Z., Song, J., Wang, Z., Zhou, L., Xia, Y., Yu, S., Sun, Q., Liu, S., Zhao, L., Li, S., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1802422115 · Cited by 33
Hiatt, S. M., Neu, M. B., Ramaker, R. C., Hardigan, A. A., Prokop, J. W., Hančárová, M., Prchalová, D., Havlovičová, M., Prchal, J., Stránecký, V., et al. (2018) · PLoS Genetics · doi:10.1371/journal.pgen.1007671 · Cited by 36
佐藤哲也, Arakawa, M., Tashima, Y., Tsuboi, E., Burdon, G., Trojan, J., Koyano, T. K., Youn, Y., Penov, K., Pedroza, A. J., et al. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.118.008543 · Cited by 35
Real-Time In-Cell NMR Reveals the Intracellular Modulation of GTP-Bound Levels of RAS
Zhao, Q., Fujimiya, R., Kubo, S., Marshall, C. B., Ikura, M., Shimada, I., & Nishida, N. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108074 · Cited by 36
ERK Inhibitor LY3214996-Based Treatment Strategies forRAS-Driven Lung Cancer
Köhler, J., Zhao, Y., Li, J., Gokhale, P. C., Tiv, H. L., Knott, A., Wilkens, M. K., Soroko, K. M., Lin, M., Ambrogio, C., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0531 · Cited by 36
Pour, F. K., Keivan, M., Ramazii, M., Ghaedrahmati, F., Anbiyaiee, A., Panahandeh, S., Khoshnam, S. E., & Farzaneh, M. (2021) · Breast Disease · doi:10.3233/bd-201063 · Cited by 37
Osumi, H., Vecchione, L., Keilholz, U., Vollbrecht, C., Alig, A. H. S., von Einem, J. C., Stahler, A., Striefler, J. K., Kurreck, A., Kind, A. J., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.05.010 · Cited by 38
The Genomic Landscape of Melanoma and Its Therapeutic Implications
Yang, T., Yu, S., Ke, C. K., & Cheng, S. (2023) · Genes · doi:10.3390/genes14051021 · Cited by 36
Intracellular nanoparticle delivery by oncogenic KRAS-mediated macropinocytosis
Liu, X., & Ghosh, D. (2019) · International Journal of Nanomedicine · doi:10.2147/ijn.s212861 · Cited by 35
Siljamäki, E., Rappu, P., Riihilä, P., Nissinen, L. M., Kähäri, V., & Heino, J. (2019) · Matrix Biology · doi:10.1016/j.matbio.2019.09.001 · Cited by 35
Targeting KRAS in Colorectal Cancer
Wang, C., & Fakih, M. (2021) · Current Oncology Reports · doi:10.1007/s11912-021-01022-0 · Cited by 35
Liang, L., & Qiu, L. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.120457 · Cited by 34
Small molecule Son of Sevenless 1 (SOS1) inhibitors: a review of the patent literature
Thompson, S. K., Buckl, A. K., Dossetter, A. G., Griffen, E., & Gill, A. L. (2021) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2021.1952984 · Cited by 35
Divergent Mechanisms Activating RAS and Small GTPases Through Post-translational Modification
Osaka, N., Hirota, Y., Ito, D., Ikeda, Y., Kamata, R., Fujii, Y., Chirasani, V. R., Campbell, S. L., Takeuchi, K., Senda, T., et al. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.707439 · Cited by 35
Peri, A., Greenstein, E., Alon, M., Pai, J. A., Dingjan, T., Reich-Zeliger, S., Barnea, E., Barbolin, C., Levy, R., Arnedo-Pac, C., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci129466 · Cited by 36
Options of Therapeutics and Novel Delivery Systems of Drugs for the Treatment of Melanoma
Wang, H., Tran, T., Duong, K. T., Nguyen, T. B., & Le, U. M. (2022) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.2c00775 · Cited by 34
Natural TCRs targeting KRASG12V display fine specificity and sensitivity to human solid tumors
Bear, A. S., Nadler, R. B., O’Hara, M. H., Stanton, K. L., Xu, C. B., Saporito, R., Rech, A. J., Baroja, M. L., Blanchard, T., Elliott, M. H., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci175790 · Cited by 35
Molecular Complexity of Colorectal Cancer: Pathways, Biomarkers, and Therapeutic Strategies
Yang, Z., Wang, X., Zhou, H., Jiang, M., Wang, J., & Sui, B. (2024) · Cancer Management and Research · doi:10.2147/cmar.s481656 · Cited by 38
Dampening oncogenic RAS signaling
Bivona, T. G. (2019) · Science · doi:10.1126/science.aav6703 · Cited by 33
Kazi, A., Chen, L., Xiang, S., Vangipurapu, R., Yang, H., Beato, F., Fang, B., Williams, T. M., Husain, K. M., Underwood, P. W., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4781 · Cited by 33
Novel Genomic Insights into Body Size Evolution in Cetaceans and a Resolution of Peto’s Paradox
Sun, D., Chai, S., Huang, X., Wang, Y., Xiao, L., Xu, S., & Yang, G. Z. (2021) · The American Naturalist · doi:10.1086/717768 · Cited by 32
The mechanism of activation of MEK1 by B-Raf and KSR1
Maloney, R., Zhang, M., Liu, Y., Jang, H., & Nussinov, R. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04296-0 · Cited by 33
Garrigou, M., Sauvagnat, B., Duggal, R., Boo, N., Gopal, P., Johnston, J. M., Partridge, A. W., Sawyer, T. K., Biswas, K., & Boyer, N. C. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00154 · Cited by 35
Zhang, Y., Li, C., Xia, C., Wah To, K. K., Guo, Z., Ren, C., Wen, L., Wang, F., Fu, L., & Liao, N. (2022) · Cell Communication and Signaling · doi:10.1186/s12964-022-00955-8 · Cited by 33
Murray, J. I., Zhang, L., Simon, A., Elipe, M. V. S., Wei, C. S., Caille, S., & Parsons, A. T. (2022) · Organic Process Research & Development · doi:10.1021/acs.oprd.2c00332 · Cited by 31
Salem, M. M., Gerges, M. N., & Noser, A. A. (2022) · Scientific Reports · doi:10.1038/s41598-022-26571-7 · Cited by 33
Murage, N. W., Ahmed, N. M., Underwood, T., Walters, Z. S., & Breininger, S. P. (2023) · Cancer and Metastasis Reviews · doi:10.1007/s10555-023-10088-0 · Cited by 32
Targeting KRAS in Colorectal Cancer: A Bench to Bedside Review
Bteich, F., Mohammadi, M., Li, T., Bhat, M. A., Sofianidi, A. A., Wei, N., & Kuang, C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241512030 · Cited by 34
Malarvannan, M., Unnikrishnan, S., Monohar, S., Ravichandiran, V., & Paul, D. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.107984 · Cited by 34
MAPK/ERK signaling pathway in rheumatoid arthritis: mechanisms and therapeutic potential
Xie, J., Sun, S., Li, Q., Chen, Y., Huang, L., Wang, D., & Wang, Y. (2025) · PeerJ · doi:10.7717/peerj.19708 · Cited by 32
Lißewski, C., Chune, V., Pantaleoni, F., Luca, A. D., Capri, Y., Brinkmann, J., Lepri, F. R., Daniele, P., Leenders, E. K. S. M., Mazzanti, L., et al. (2020) · European Journal of Human Genetics · doi:10.1038/s41431-020-00708-6 · Cited by 32
Wu, S., Guo, X., Zhou, J., Zhu, X., Chen, H., Zhang, K., Lu, Y., & Chen, Y. (2020) · Aging · doi:10.18632/aging.103639 · Cited by 33
Ras, PI3K and mTORC2 – three's a crowd?
Smith, S. F., Collins, S. E., & Charest, P. G. (2020) · Journal of Cell Science · doi:10.1242/jcs.234930 · Cited by 34
Endolysosomal TRPMLs in Cancer
Xu, M., & Dong, X. (2021) · Biomolecules · doi:10.3390/biom11010065 · Cited by 33
Targeting RAS oncogenesis with SOS1 inhibitors
Hillig, R. C., & Bader, B. (2022) · Advances in cancer research · doi:10.1016/bs.acr.2021.07.001 · Cited by 33
KRAS-Mutant Non-Small-Cell Lung Cancer: From Past Efforts to Future Challenges
Ceddia, S., Landi, L. M., & Cappuzzo, F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23169391 · Cited by 35
Ha, D. P., Huang, B., Wang, H., Rangel, D. F., Krieken, R. V., Liu, Z., Samanta, S., Neamati, N., & Lee, A. S. (2022) · Neoplasia · doi:10.1016/j.neo.2022.100837 · Cited by 33
Delineating the RAS Conformational Landscape
Parker, M. I., Meyer, J. E., Golemis, E. A., & Dunbrack (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-0804 · Cited by 30
Targeting the DNA replication stress phenotype of KRAS mutant cancer cells
Zubaidi, T. A., Gehrisch, O. H. F., Genois, M., Liu, Q., Lü, S., Kung, J., Xie, Y., Schuemann, J., Lu, H., Hata, A. N., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-83142-y · Cited by 34
Direct K-Ras Inhibitors to Treat Cancers: Progress, New Insights, and Approaches to Treat Resistance
Nussinov, R., & Jang, H. (2023) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-022823-113946 · Cited by 32
Functional and structural insights into RAS effector proteins
Mozzarelli, A. M., Simanshu, D. K., & Castel, P. (2024) · Molecular Cell · doi:10.1016/j.molcel.2024.06.027 · Cited by 33
Self-citationNussinov, R. (2025) · Journal of Molecular Biology · doi:10.1016/j.jmb.2025.169044 · Cited by 34
Zaborsky, N., Gassner, F. J., Höpner, J. P., Schubert, M., Hebenstreit, D., Stark, R., Asslaber, D., Steiner, M. J., Geisberger, R., Greil, R., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0260-4 · Cited by 31
Martin, E., Lamba, N., Flucke, U. E., Verhoef, C. K., Coert, J. H., Versleijen‐Jonkers, Y. M. H., & Desar, I. M. E. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.04.007 · Cited by 31
Mehaffey, M. R., Schardon, C. L., Novelli, E. T., Cammarata, M. B., Webb, L. J., Fast, W. L., & Brodbelt, J. S. (2019) · Chemical Science · doi:10.1039/c9sc01032g · Cited by 31
Genetic basis of neurofibromatosis type 1 and related conditions, including mosaicism
Legius, E., & Brems, H. (2020) · Child s Nervous System · doi:10.1007/s00381-020-04771-8 · Cited by 30
The Myc and Ras Partnership in Cancer: Indistinguishable Alliance or Contextual Relationship?
Mahauad‐Fernandez, W. D., & Felsher, D. W. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-0787 · Cited by 31
RAS Function in cancer cells: translating membrane biology and biochemistry into new therapeutics
Kattan, W. E., & Hancock, J. F. (2020) · Biochemical Journal · doi:10.1042/bcj20190839 · Cited by 33
Pulmonary metastasectomy in colorectal carcinoma
Beckers, P. A. J., Berzenji, L., Yogeswaran, S. K., Lauwers, P., Bilotta, G., Shkarpa, N., Hendriks, J. M., & Schil, P. E. V. (2021) · Journal of Thoracic Disease · doi:10.21037/jtd-2019-pm-14 · Cited by 31
Selumetinib: a selective MEK1 inhibitor for solid tumor treatment
Hedayat, M., Jafari, R., & Zolbanin, N. M. (2022) · Clinical and Experimental Medicine · doi:10.1007/s10238-021-00783-z · Cited by 32
Pan, Z., Wei, X., Li, S.-J., Guo, H., Li, Z., Zhang, K.-K., Lyu, Q., Liu, W., Yang, Q., & Cheng, D. (2022) · Oncogenesis · doi:10.1038/s41389-022-00390-x · Cited by 33
Li, M.-Y., Wang, Y., Fan, J., Zhuang, H., Liu, Y., Ji, D., & Lu, S. (2022) · Journal of Molecular Biology · doi:10.1016/j.jmb.2022.167730 · Cited by 30
A double‐edged sword: The world according to Capicua in cancer
Tanaka, M., Yoshimoto, T., & Nakamura, T. (2017) · Cancer Science · doi:10.1111/cas.13413 · Cited by 31
Oncogenic KRAS engages an RSK1/NF1 pathway to inhibit wild-type RAS signaling in pancreatic cancer
Cheng, D. K., Oni, T. E., Thalappillil, J. S., Park, Y., Ting, H.-C., Alagesan, B., Prasad, N. V., Addison, K., Rivera, K. D., Pappin, D. J., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2016904118 · Cited by 30
“Intrinsically, KRAS slowly hydrolyzes GTP into GDP to halt signaling; however, GTPase activating proteins (GAPs) such as neurofibromin 1(NF1) catalyze this process (20).”
Navarro-Jiménez, M., González, B., Mulet-Margalef, N., Hierro, C., & Alonso, S. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-01166-3 · Cited by 38
Genetic Testing to Guide Risk-Stratified Screens for Breast Cancer
Willoughby, A., Andreassen, P. R., & Toland, A. E. (2019) · Journal of Personalized Medicine · doi:10.3390/jpm9010015 · Cited by 31
Henry, J. T., & Johnson, B. (2019) · Chinese Clinical Oncology · doi:10.21037/cco.2019.08.08 · Cited by 29
Computationally Empowered Workflow Identifies Novel Covalent Allosteric Binders for KRASG12C
Mortier, J., Friberg, A., Badock, V., Moosmayer, D., Schroeder, J., Steigemann, P., Siegel, F., Gradl, S., Bauser, M., Hillig, R. C., et al. (2020) · ChemMedChem · doi:10.1002/cmdc.201900727 · Cited by 29
The Emerging Role of Ras Pathway Signaling in Pediatric Cancer
Ney, G. M., McKay, L. M., Koschmann, C. J., Mody, R. J., & Li, Q. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-0916 · Cited by 32
Novel regulation of Ras proteins by direct tyrosine phosphorylation and dephosphorylation
Buday, L., & Vas, V. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09918-2 · Cited by 30
Signaling pathways downstream to receptor tyrosine kinases: targets for cancer treatment
Cordover, E., & Minden, A. (2020) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2020.101 · Cited by 31
Hidden Targets in RAF Signalling Pathways to Block Oncogenic RAS Signalling
Nolan, A. A., Aboud, N. K., Kölch, W., & Matallanas, D. (2021) · Genes · doi:10.3390/genes12040553 · Cited by 29
Transgenic mouse models of breast cancer
Regua, A. T., Arrigo, A., Doheny, D. L., Wong, G. L., & Lo, H. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.05.027 · Cited by 35
Rozengurt, E., & Eibl, G. (2021) · Cancers · doi:10.3390/cancers13205126 · Cited by 31
Chen, J., Zhang, S., Zeng, Q., Wang, W., Zhang, Q., & Liu, X. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.912518 · Cited by 30
Progress of small molecules for targeted protein degradation: PROTACs and other technologies
Zhao, H., Xin, M., & Zhang, S. (2023) · Drug Development Research · doi:10.1002/ddr.22026 · Cited by 31
Ramalingam, P. S., Balakrishnan, P., Rajendran, S., Jothi, A., Rajasekaran, R., & Arumugam, S. (2023) · Current Issues in Molecular Biology · doi:10.3390/cimb45030137 · Cited by 32
IL-1β and Statin Treatment in Patients with Myocardial Infarction and Diabetic Cardiomyopathy
Liberale, L., Carbone, F., Camici, G. G., & Montecucco, F. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8111764 · Cited by 31
Fragment-based drug discovery of triazole inhibitors to block PDEδ-RAS protein-protein interaction
Chen, D., Chen, Y., Lian, F., Chen, L., Li, Y., Cao, D., Wang, X., Chen, L., Li, J., Meng, T., et al. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.12.018 · Cited by 31
Germline mutations in a G protein identify signaling cross-talk in T cells
Ham, H., Jing, H., Lamborn, I. T., Kober, M. M., Koval, A., Berchiche, Y. A., Anderson, D. E., Druey, K. M., Mandl, J. N., Isidor, B., et al. (2024) · Science · doi:10.1126/science.add8947 · Cited by 31
Unleashing the Power of Covalent Drugs for Protein Degradation
Fu, M., Jin, H., Wang, S., Shen, L., Liu, H., Liu, Y., Zheng, Y., & Dai, X. (2025) · Medicinal Research Reviews · doi:10.1002/med.22101 · Cited by 31
Network-Based Predictors of Progression in Head and Neck Squamous Cell Carcinoma
Sanati, N., Iancu, O. D., Wu, G., Jacobs, J. E., & McWeeney, S. K. (2018) · Frontiers in Genetics · doi:10.3389/fgene.2018.00183 · Cited by 31
Halawa, A. H., Eskandrani, A. A., Elgammal, W. E., Hassan, S. M., Hassan, A. A. E.-H., Ebrahim, H. Y., Mehany, A. B. M., El-Agrody, A. M., & Okasha, R. M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225592 · Cited by 29
Somatic variants in new candidate genes identified in focal cortical dysplasia type II
Zhang, Z., Gao, K., Liu, Q., Zhou, J., Li, X., Lang, N., Liu, M., Wang, T., Zhang, J., Wang, H., et al. (2020) · Epilepsia · doi:10.1111/epi.16481 · Cited by 29
Capturing the primordial Kras mutation initiating urethane carcinogenesis
Li, S., MacAlpine, D. M., & Counter, C. M. (2020) · Nature Communications · doi:10.1038/s41467-020-15660-8 · Cited by 28
Advances in Targeted Therapy and Immunotherapy for Pancreatic Cancer
Liu, X., Li, Z., & Wang, Y. (2021) · Advanced Biology · doi:10.1002/adbi.201900236 · Cited by 29
LZTR1: A promising adaptor of the CUL3 family (Review)
Zhang, H., Cao, X., Wang, J., Li, Q., Zhao, Y., & Jin, X. (2021) · Oncology Letters · doi:10.3892/ol.2021.12825 · Cited by 27
Small-Molecule RAS Inhibitors as Anticancer Agents: Discovery, Development, and Mechanistic Studies
Shetu, S. A., & Bandyopadhyay, D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073706 · Cited by 31
Biomarkers in Metastatic Colorectal Cancer: Status Quo and Future Perspective
Puccini, A., Seeber, A., & Berger, M. D. (2022) · Cancers · doi:10.3390/cancers14194828 · Cited by 31
Metadata
- Authors
- Simanshu, D. K., Nissley, D. V., & McCormick, F.
- Affiliations
- Frederick National Laboratory for Cancer Research (US)
- University of California, San Francisco (US)
- Corresponding author
- McCormick, Frank
- Venue
- Cell
- Publisher
- Elsevier BV
- Published
- 2017-06
- Volume
- 170
- Issue
- 1
- Pages
- 17-33
- ISSN
- 0092-8674 (ISSN-L)
- PMC
- PMC5555610
- OpenAlex
- W2732767128
- Cited by
- 1,943
- References
- 162
- Citations by year
- 2026: 210 · 2025: 263 · 2024: 276 · 2023: 247 · 2022: 267 · 2021: 247 · 2020: 194 · 2019: 143 · 2018: 82 · 2017: 12
- FWCI
- 11.03
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Cell (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Cancer Institute
- NIH (HHSN261200800001E)
- Outstanding Investigator Award (5R35CA197709)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Cellular transport and secretion
- Keywords
- Ras proteins, Ras signaling, RASopathies, cancer, mental illness, RAS mutations, signal transduction, membrane binding, Ras activation
- MeSH terms
- Congenital Abnormalities, Animals, Mental Disorders, Cell Membrane, Humans, Mutation, Neoplasms, Phylogeny, Yeasts, Signal Transduction, ras Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
